Alcon Inc. (ALC) News
Filter ALC News Items
ALC News Results
|Loading, please wait...|
ALC News Highlights
- For ALC, its 30 day story count is now at 15.
- Over the past 9 days, the trend for ALC's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- BEAT, AG and CC are the most mentioned tickers in articles about ALC.
Latest ALC News From Around the Web
Below are the latest news stories about Alcon Inc that investors may wish to consider to help them evaluate ALC as an investment opportunity.
Alcon AG (NYSE: ALC ) reported Q4 FY21 sales of $2.13 billion , +11% Y/Y on a reported basis and +13% on a constant currency (cc) basis, beating the consensus of $2.04 billion. Eye care markets in the fourth quarter reflected the recovery in the U.S. and the continuing recovery internationally from the COVID-19 pandemic. It reported a core EPS of $0.56, surpassing the Wall Street estimate of $0.49, … Full story available on Benzinga.com
No summary available.
No summary available.
According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.
Alcon (NYSE:ALC) stock is trading 5% higher in after-hours trading after the company reported Q4 2021 earnings that beat on both the bottom and top lines. The company also provided bullish revenue and earnings guidance for 2022. Diluted EPS in Q4 of $0.28 was a ~47% increase from Q4 2020. Revenue of...
GENEVA--(BUSINESS WIRE)--Alcon Reports Fourth Quarter and Full Year 2021 Results
Alcon stock is trading 5% higher in after-hours trading after the company reported Q4 2021 earnings that beat on both the bottom and top lines.
Alcon press release (ALC): Q4 Non-GAAP EPS of $0.56 beats by $0.06.Revenue of $2.13B (+10.4% Y/Y) beats by $30M.FY22 Guidace:Net sales of $8.7B-$8.9B.Core EPS of $2.35-$2.45.
Alcon (NYSE:ALC) is scheduled to announce Q4 earnings results on Tuesday, Feb. 15, after market close.The consensus EPS estimate is $0.50 (+11.1% Y/Y)
Written by Nick Ackerman, co-produced by Stanford Chemist BlackRock Health Sciences Trust II (BMEZ) has been having a tough time performing. That is despite its exposure to healthcare as it is invested heavier in the healthcare innovation/growth space. It also has private holdings that also can increase its risk level....